Innovation Pharmaceuticals Inc logo

Innovation Pharmaceuticals Inc

$ 0.02 -0.00135 (-5.97%) 10:08 PM EST
P/E:
At Loss
P/B:
2.13
Market Cap:
$ 10.71M
Enterprise V:
$ 8.87M
Volume:
801.37K
Avg Vol (2M):
635.99K
Volume:
801.37K
Market Cap $:
10.71M
PE Ratio:
At Loss
Avg Vol (2-Month):
635.99K
Enterprise Value $:
8.87M
PB Ratio:
2.13
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 6.6
Equity-to-Asset 0.37
Debt-to-Equity 0.13
Debt-to-EBITDA -0.08
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -19.87
Distress
Grey
Safe
Beneish M-Score -2.61
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 27.4
3-Year EPS without NRI Growth Rate 41.5
3-Year FCF Growth Rate 28.8

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 33.79
9-Day RSI 33.86
14-Day RSI 34.8
6-1 Month Momentum % 6.47
12-1 Month Momentum % -53.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.6
Quick Ratio 0.6
Cash Ratio 0.58

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -35.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -33983.33
Net Margin % -35627.78
ROE % -109.78
ROA % -54.19
ROIC % -120.6
ROCE % -93.09

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 2.13
EV-to-EBIT -1.4
EV-to-EBITDA -1.49
EV-to-Revenue 492.89
EV-to-FCF -1.71
Earnings Yield (Greenblatt) % -71.43

Financials

IPIX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:IPIX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.018
EPS (TTM) ($) -0.01
Beta -0.15
Volatility % 90.63
14-Day RSI 34.8
14-Day ATR ($) 0.003821
20-Day SMA ($) 0.024936
12-1 Month Momentum % -53.71
52-Week Range ($) 0.019 - 0.073
Shares Outstanding (Mil) 503.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Innovation Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Innovation Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.